Physician profile
Gail Calvert
NPI 1922690254
$4,687.55
in general payments reported to CMS, 2019-2025
53 companies · $553 in 2025
The $553 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,380 · 2022: $1,916 · 2023: $493 · 2024: $345 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,360 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,359.67 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $456.92 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $360.74 | 2021-2022 | |
| Seagen INC. | $357.29 | 2021-2023 | Tukysa |
| Incyte Corporation | $249.99 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $226.01 | 2021-2024 | Breztri |
| Amgen INC. | $195.88 | 2021-2023 | Blincyto, Kyprolis |
| E.R. Squibb & Sons, L.L.C. | $192.54 | 2022 | |
| Novartis Pharmaceuticals Corporation | $175.90 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $173.51 | 2022-2025 | Rexulti |
| Janssen Biotech, INC. | $154.42 | 2022-2023 | Erleada |
| Pfizer INC. | $150.37 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $136.36 | 2025 | Caplyta |
| Eisai INC. | $132.09 | 2022 | |
| Lilly USA, LLC | $116.24 | 2021-2024 | Jardiance, Mounjaro, Zepbound |
| Viatris Specialty LLC | $115.75 | 2025 | Yupelri |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gail Calvert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.